

Aaron Broadwell, MD
President

May 22, 2025

Gary Feldman, MD
Immediate Past President

House of Representatives
900 North 3rd Street
Baton Rouge, LA 70804

Madelaine Feldman, MD
VP, Advocacy & Government Affairs

Michael Saitta, MD, MBA
Treasurer

Re: Support HB 264– Pass Drug Rebates back to the Patient

Firas Kassab, MD
Secretary

Members of the House of Representatives:

Erin Arnold, MD
Director

The Coalition of State Rheumatology Organizations (CSRO) and the Rheumatology Alliance of Louisiana (RAL) support **HB 264**, which would require pharmacy benefit managers to pass drug rebates back to the patient. CSRO and RAL serve the practicing rheumatologist and is comprised of over 40 state rheumatology societies nationwide with a mission of advocating for excellence in the field of rheumatology and ensuring access to the highest quality of care for the management of rheumatologic and musculoskeletal disease.

Leyka Barbosa, MD
Director

Kostas Botsoglou, MD
Director

Mark Box, MD
Director

Rheumatologic diseases, such as rheumatoid arthritis, psoriatic arthritis and lupus, are systemic and incurable, but innovations in medicine over the last several decades have enabled rheumatologists to better manage these conditions. With access to the right treatment early in the disease, patients can generally delay or even avoid damage to their bones and joints, as well as reduce reliance on pain medications and other ancillary services, thus improving their quality of life.

Michael Brooks, MD
Director

Amish Dave, MD, MPH
Director

PBM Practices Harm Patients

Rheumatology patients were among the first to experience the harmful repercussions of pharmacy benefit manager (PBM) business practices because rheumatologic conditions regularly require complex, and often expensive, specialty medications. These PBM business practices were built on a system of perverse incentives, where the higher a drug's list price, the greater the income potential for the PBM. As a result, prescription drug formularies are designed to maximize PBM revenues. Time and time again, we've seen our patients switched between different medications when PBMs change their formularies to higher-priced drugs when they have more to gain from rebates and fees set at a percentage of the list price. These tactics benefit the PBMs financially, while our patients see none of the savings accrued to the PBMs.

Harry Gewanter, MD, MACR
Director

Adrienne Hollander, MD
Director

Robert Levin, MD
Director

Amar Majjhoo, MD
Director

Gregory Niemer, MD
Director

Joshua Stollow, MD
Director

The three largest PBMs—Caremark Rx, Express Scripts (ESI), and OptumRx—control 80% of the prescriptions filled in the United States, according to the Federal Trade Commission.¹ This vertical integration allows the PBMs to control which medication patients can take (through formulary construction), when they can take these medications (through utilization management), where they can purchase their medications (through pharmacy networks), and how much they must pay for their drugs (through cost-sharing). Currently, all of these decision points are leveraged to maximize PBM profits rather than provide the patient with the best care at the greatest savings. This consolidated healthcare system is not good for patients or the government as it causes competition that only raises drug prices.

EXECUTIVE OFFICE

Leslie Del Ponte
Executive Director

Formulary design decisions are disastrous for patients who pay coinsurance because their out-of-pocket cost is based on list price of the medication – not what the PBM actually pays. An analysis by Drug Channels estimates that the spread between list and net price for insurers was over \$200 billion in 2021.ⁱⁱ A 2021 report by the Texas Department of Insurance demonstrated that patients see marginal benefit from the supposed PBM “savings.” Of \$5,709,118,113 in rebates generated by PBMs for Texas insurers, only 21% made it back to patients in the form of direct savings.ⁱⁱⁱ

Pass Manufacturer Rebates Directly onto Patients

PBMs claim to negotiate aggressive rebates and discounts that supposedly benefit employers and help keep premiums down. However, as demonstrated in the Texas report, those “savings” rarely trickle down to the patient. List prices appear to be fictional for everyone *except* the patient, whose cost-sharing is often based on the full price. It’s time for rebates and other price concessions to benefit the patient – not the PBMs, especially as many patients are enrolled in health insurance plans that utilize high deductibles and/or significant cost sharing.

CSRO and RAL support **HB 264** as it would require manufacturer rebates to bypass the PBM and require 100% of the rebates to go directly to the patient at the point of sale. It would also require that when a rebate exceeds the patient’s cost-sharing responsibility, the remaining rebate amount is sent to the employer or sponsor of the health plan. We appreciate the sponsor’s thoughtfulness in ensuring that rebates do not go back to the health plan. Given the immense vertical integration of PBMs and health insurance companies, policies that allow rebates to go directly to the health plan may have little impact in reducing patient expenses. Instead, rebates that go directly to the patient allow patients to see *immediate* savings at the point of sale, with additional rebate savings supporting Louisiana employers. Not only will reducing patients’ out-of-pocket costs improve adherence with better health outcomes, but it will also foster transparency and fairness in the healthcare system.

On behalf of practicing rheumatologists throughout Louisiana and the patients we serve, we request that you support **HB 264**. We thank you for your consideration and are happy to further detail our comments to the committee upon request.

Respectfully,



Aaron Broadwell, MD, FACR
President
Board of Directors, CSRO



Madelaine A. Feldman, MD, FACR
VP, Advocacy & Government Affairs
Board of Directors, CSRO
Director, RAL

ⁱ Federal Trade Commission. “[FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices](#).” September 2024.

ⁱⁱ Drug Channels. “[Warped Incentives Update: The Gross-to-Net Bubble Exceeded \\$200 Billion in 2021 \(rerun\)](#).” July 2022.

ⁱⁱⁱ Texas Department of Insurance. “[Prescription Drug Cost Transparency-Pharmacy Benefit Managers](#)”. 2021.